The dual effect of acetate on microglial TNF-α production

Detalhes bibliográficos
Autor(a) principal: Fragas, Matheus Garcia
Data de Publicação: 2022
Outros Autores: Oliveira, Daniel May de, Hiyane, Meire Ioshie, Braga, Tarcio Teodoro, Camara, Niels Olsen Saraiva
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/213420
Resumo: Introduction: Short-Chain Fatty Acids (SCFA) are products of intestinal microbial metabolism that can reach the brain and alter microglia in health and disease contexts. However, data are conflicting on the effect of acetate, the most abundant SCFA in the blood, in these cells. Objective: The authors aimed to investigate acetate as a modulator of the inflammatory response in microglia stimulated with LPS. Method: The authors used an immortalized cell line, C8-B4, and primary cells for in vitro treatments with acetate and LPS. Cell viability was analyzed by MTT, cytokine by RT-PCR, ELISA, and flow cytometry. The authors also performed in vivo and in silico analyses to study the role of acetate and the TNF-α contribution to the development of Experimental Autoimmune Encephalomyelitis (EAE). Results: Acetate co-administered with LPS was able to exacerbate the production of pro-inflammatory cytokines at gene and protein levels in cell lines and primary culture of microglia. However, the same effects were not observed when acetate was administered alone or as pretreatment, prior to the LPS stimulus. Additionally, pharmacological inhibition of histone deacetylase concomitantly with acetate and LPS led to decreased TNF-α production. In silico analysis showed a crucial role of the TNF-α pathway in EAE development. Moreover, acetate administration in vivo during the initial phase of EAE led to a better disease outcome and reduced TNF-α production. Conclusion: Treatment with acetate was able to promote the production of TNF-α in a concomitant LPS stimulus of microglia. However, the immune modulation of microglia by acetate pretreatment may be a component in the generation of future therapies for neurodegenerative diseases.
id USP-19_da3a92d17844b554e4e1fe432e9a1760
oai_identifier_str oai:revistas.usp.br:article/213420
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling The dual effect of acetate on microglial TNF-α productionAcetateMicrogliaInflammationAlzheimer DiseaseEncephalomyelitisTNFaNeuropharmacologyIntroduction: Short-Chain Fatty Acids (SCFA) are products of intestinal microbial metabolism that can reach the brain and alter microglia in health and disease contexts. However, data are conflicting on the effect of acetate, the most abundant SCFA in the blood, in these cells. Objective: The authors aimed to investigate acetate as a modulator of the inflammatory response in microglia stimulated with LPS. Method: The authors used an immortalized cell line, C8-B4, and primary cells for in vitro treatments with acetate and LPS. Cell viability was analyzed by MTT, cytokine by RT-PCR, ELISA, and flow cytometry. The authors also performed in vivo and in silico analyses to study the role of acetate and the TNF-α contribution to the development of Experimental Autoimmune Encephalomyelitis (EAE). Results: Acetate co-administered with LPS was able to exacerbate the production of pro-inflammatory cytokines at gene and protein levels in cell lines and primary culture of microglia. However, the same effects were not observed when acetate was administered alone or as pretreatment, prior to the LPS stimulus. Additionally, pharmacological inhibition of histone deacetylase concomitantly with acetate and LPS led to decreased TNF-α production. In silico analysis showed a crucial role of the TNF-α pathway in EAE development. Moreover, acetate administration in vivo during the initial phase of EAE led to a better disease outcome and reduced TNF-α production. Conclusion: Treatment with acetate was able to promote the production of TNF-α in a concomitant LPS stimulus of microglia. However, the immune modulation of microglia by acetate pretreatment may be a component in the generation of future therapies for neurodegenerative diseases.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2022-06-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/21342010.1016/j.clinsp.2022.100062Clinics; Vol. 77 (2022); 100062Clinics; v. 77 (2022); 100062Clinics; Vol. 77 (2022); 1000621980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/213420/195410Copyright (c) 2023 Clinicsinfo:eu-repo/semantics/openAccessFragas, Matheus GarciaOliveira, Daniel May deHiyane, Meire Ioshie Braga, Tarcio TeodoroCamara, Niels Olsen Saraiva2023-07-06T13:04:57Zoai:revistas.usp.br:article/213420Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:04:57Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv The dual effect of acetate on microglial TNF-α production
title The dual effect of acetate on microglial TNF-α production
spellingShingle The dual effect of acetate on microglial TNF-α production
Fragas, Matheus Garcia
Acetate
Microglia
Inflammation
Alzheimer Disease
Encephalomyelitis
TNFa
Neuropharmacology
title_short The dual effect of acetate on microglial TNF-α production
title_full The dual effect of acetate on microglial TNF-α production
title_fullStr The dual effect of acetate on microglial TNF-α production
title_full_unstemmed The dual effect of acetate on microglial TNF-α production
title_sort The dual effect of acetate on microglial TNF-α production
author Fragas, Matheus Garcia
author_facet Fragas, Matheus Garcia
Oliveira, Daniel May de
Hiyane, Meire Ioshie
Braga, Tarcio Teodoro
Camara, Niels Olsen Saraiva
author_role author
author2 Oliveira, Daniel May de
Hiyane, Meire Ioshie
Braga, Tarcio Teodoro
Camara, Niels Olsen Saraiva
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Fragas, Matheus Garcia
Oliveira, Daniel May de
Hiyane, Meire Ioshie
Braga, Tarcio Teodoro
Camara, Niels Olsen Saraiva
dc.subject.por.fl_str_mv Acetate
Microglia
Inflammation
Alzheimer Disease
Encephalomyelitis
TNFa
Neuropharmacology
topic Acetate
Microglia
Inflammation
Alzheimer Disease
Encephalomyelitis
TNFa
Neuropharmacology
description Introduction: Short-Chain Fatty Acids (SCFA) are products of intestinal microbial metabolism that can reach the brain and alter microglia in health and disease contexts. However, data are conflicting on the effect of acetate, the most abundant SCFA in the blood, in these cells. Objective: The authors aimed to investigate acetate as a modulator of the inflammatory response in microglia stimulated with LPS. Method: The authors used an immortalized cell line, C8-B4, and primary cells for in vitro treatments with acetate and LPS. Cell viability was analyzed by MTT, cytokine by RT-PCR, ELISA, and flow cytometry. The authors also performed in vivo and in silico analyses to study the role of acetate and the TNF-α contribution to the development of Experimental Autoimmune Encephalomyelitis (EAE). Results: Acetate co-administered with LPS was able to exacerbate the production of pro-inflammatory cytokines at gene and protein levels in cell lines and primary culture of microglia. However, the same effects were not observed when acetate was administered alone or as pretreatment, prior to the LPS stimulus. Additionally, pharmacological inhibition of histone deacetylase concomitantly with acetate and LPS led to decreased TNF-α production. In silico analysis showed a crucial role of the TNF-α pathway in EAE development. Moreover, acetate administration in vivo during the initial phase of EAE led to a better disease outcome and reduced TNF-α production. Conclusion: Treatment with acetate was able to promote the production of TNF-α in a concomitant LPS stimulus of microglia. However, the immune modulation of microglia by acetate pretreatment may be a component in the generation of future therapies for neurodegenerative diseases.
publishDate 2022
dc.date.none.fl_str_mv 2022-06-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/213420
10.1016/j.clinsp.2022.100062
url https://www.revistas.usp.br/clinics/article/view/213420
identifier_str_mv 10.1016/j.clinsp.2022.100062
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/213420/195410
dc.rights.driver.fl_str_mv Copyright (c) 2023 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 77 (2022); 100062
Clinics; v. 77 (2022); 100062
Clinics; Vol. 77 (2022); 100062
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222766636466176